123 related articles for article (PubMed ID: 14665350)
1. Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE.
Kane CJ; Lubeck DP; Knight SJ; Spitalny M; Downs TM; Grossfeld GD; Pasta DJ; Mehta SS; Carroll PR
Urology; 2003 Dec; 62(6):1035-9. PubMed ID: 14665350
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer.
Nguyen PL; Chen MH; Hoffman KE; Chen RC; Hu JC; Bennett CL; Kattan MW; Sartor O; Stein K; D'Amico AV
BJU Int; 2012 Jul; 110(2):201-5. PubMed ID: 22085233
[TBL] [Abstract][Full Text] [Related]
3. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
4. Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes.
Akaza H; Hinotsu S; Cooperberg MR; Chung BH; Youl Lee J; Umbas R; Tsukamoto T; Namiki M; Carroll P
Jpn J Clin Oncol; 2013 Jul; 43(7):756-66. PubMed ID: 23723314
[TBL] [Abstract][Full Text] [Related]
5. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
[TBL] [Abstract][Full Text] [Related]
6. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
7. Predictors of fatigue after treatment for prostate cancer.
Maliski SL; Kwan L; Orecklin JR; Saigal CS; Litwin MS
Urology; 2005 Jan; 65(1):101-8. PubMed ID: 15667873
[TBL] [Abstract][Full Text] [Related]
8. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
[TBL] [Abstract][Full Text] [Related]
9. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer.
Lubeck DP; Grossfeld GD; Carroll PR
Urology; 2001 Aug; 58(2 Suppl 1):94-100. PubMed ID: 11502459
[TBL] [Abstract][Full Text] [Related]
10. The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer.
Penson DF; Stoddard ML; Pasta DJ; Lubeck DP; Flanders SC; Litwin MS
J Clin Epidemiol; 2001 Apr; 54(4):350-8. PubMed ID: 11297885
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.
Sadetsky N; Elkin EP; Latini DM; DuChane J; Carroll PR;
Prostate Cancer Prostatic Dis; 2008; 11(3):280-7. PubMed ID: 17893700
[TBL] [Abstract][Full Text] [Related]
12. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
Barocas DA; Cowan JE; Smith JA; Carroll PR;
J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
[TBL] [Abstract][Full Text] [Related]
13. Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey.
Hall JD; Boyd JC; Lippert MC; Theodorescu D
Urology; 2003 Feb; 61(2):402-7. PubMed ID: 12597956
[TBL] [Abstract][Full Text] [Related]
14. Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time.
Bhatnagar V; Stewart ST; Bonney WW; Kaplan RM
Urology; 2004 Jan; 63(1):103-9. PubMed ID: 14751359
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
Macdonald OK; D'Amico AV; Sadetsky N; Shrieve DC; Carroll PR
Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
[TBL] [Abstract][Full Text] [Related]
16. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE.
Mehta SS; Lubeck D; Pasta DJ; Litwin MS
J Urol; 2003 Nov; 170(5):1931-3. PubMed ID: 14532810
[TBL] [Abstract][Full Text] [Related]
17. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
Moul JW; Connelly RR; Lubeck DP; Bauer JJ; Sun L; Flanders SC; Grossfeld GD; Carroll PR
J Urol; 2001 Oct; 166(4):1322-7. PubMed ID: 11547066
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation use with external beam radiation for prostate cancer: results from CaPSURE.
Park S; Meng MV; Elkin EP; Speight JL; DuChane J; Carroll PR
J Urol; 2005 Nov; 174(5):1802-7. PubMed ID: 16217291
[TBL] [Abstract][Full Text] [Related]
19. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
20. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor.
Koppie TM; Grossfeld GD; Miller D; Yu J; Stier D; Broering JM; Lubeck D; Henning JM; Flanders SC; Carroll PR
J Urol; 2000 Jul; 164(1):81-8. PubMed ID: 10840429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
